You are here: Industry Insights > CStone

News List

CStone Announces New Drug Approval of GAVRETO(R) (pralsetinib) as First Selective RET Inhibitor in China, Providing a New Therapy for a Subset of Non-Small Cell Lung Cancer Patients prnasia
March 24, 2021
CStone Pharmaceuticals, a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and precision medicines, today announces that the National Medical Products Administration (NMPA) of China has ...
China continues to lead high value oncology deals in APAC: GlobalData expresspharma
March 15, 2021
High-value deals have dominated the Asia-Pacific (APAC) pharma strategic partnership landscape in 2020. Within the region, China is well ahead of other countries, particularly in the field of oncology, reveals GlobalData.
CStone Pharmaceuticals Reports Efficacy and Safety Data from the ARROW Trial of Pralsetinib in Chinese Patients with Advanced RET Fusion-positive Non-Small Cell Lung Cancer after Platinum-based Chemot prnasia
January 28, 2021
CStone Pharmaceuticals, a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, today announced that results from a cohort of Chinese patients in the global ...
CStone and LegoChem to jointly develop novel antibody drug conjugate pharmaceutical-technology
October 30, 2020
CStone Pharmaceuticals and LegoChem Biosciences (LCB) have signed a licensing agreement for the development and commercialisation of a potential antibody-drug conjugate (ADC), LCB71.
CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate prnasia
October 29, 2020
CStone Pharmaceuticals announced today a licensing agreement with LegoChem Biosciences, Inc., for the development and commercialization of LCB71, a potential first-in-class/best-in-class antibody drug conjugate ("ADC").
CStone Announces Completion of $200 million Share Sale to Pfizer prnasia
October 16, 2020
CStone Pharmaceuticals announced today the completion of the Share Subscription Agreement through which an affiliate of Pfizer Inc. subscribed for newly issued CStone shares at approximately US$200 million (equivalent to approximately HK$1.55 billion)...
Pfizer and CStone to collaborate for oncology therapies in China expresspharma
October 09, 2020
CStone to receive up to $280 million in milestone payments for sugemalimab, and additional royalties.
CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab (CS1001) At 2020 CSCO Annual Meeting prnasia
September 27, 2020
CStone Pharmaceuticals (Suzhou) Co., Ltd. announced the updated results from two studies of its anti-PD-L1 monoclonal antibody sugemalimab (CS1001) at the 2020 Chinese Society of Clinical Oncology (CSCO) Annual Meeting.
CStone Announces Preliminary Results from a Bridging Study of Avapritinib in Chinese Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors at the 2020 CSCO Annual Meeting prnasia
September 27, 2020
CStone Pharmaceuticals (SUZHOU) Co., Ltd. presented positive results at the 2020 Chinese Society of Clinical Oncology (CSCO) Annual Meeting from a phase I/II bridging study in China evaluating avapritinib in patients with unresectable or metastatic ...
CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma prnasia
January 09, 2020
CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) announced that the first patient has been dosed in the Phase III GEMSTONE-304 study of the Company's anti-PD-L1 antibody CS1001 in combination therapy as first-line treatment in patients with

Previous page 1 2 3 4 5 Next page